Platelet function testing in cardiovascular diseases.

about

Patterns and levels of platelet glycosylation in patients with coronary heart disease and type 2 diabetes mellitus.Increased proatherogenic monocyte-platelet cross-talk in monocyte subpopulations of patients with stable coronary artery disease.

P2860

Q50070058-961D7B91-0CC7-4840-BB10-A27E6B296A15 Q53086984-3620BE78-49AA-41A4-A880-7E4CF3C39F9B

P2860

Platelet function testing in cardiovascular diseases.

Item

http://www.wikidata.org/entity/Q36270009

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

2005年學術文章

@zh

2005年學術文章

@zh-hant

name

Platelet function testing in cardiovascular diseases.

@ast

Platelet function testing in cardiovascular diseases.

@en

type

Item

label

Platelet function testing in cardiovascular diseases.

@ast

Platelet function testing in cardiovascular diseases.

@en

prefLabel

Platelet function testing in cardiovascular diseases.

@ast

Platelet function testing in cardiovascular diseases.

@en

P1476

Platelet function testing in cardiovascular diseases.

@en

P2093

Alan D Michelson

http://www.w3.org/2001/XMLSchema#string

P2860

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients

Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment

Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction

Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation

Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events

Aspirin non-responder status in patients with recurrent cerebral ischemic attacks

A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease

Platelets in atherothrombosis.

Soluble CD40L and cardiovascular risk in women.

Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multicenter study.

P304

132-137

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/10245330512331390186

http://www.w3.org/2001/XMLSchema#string

P478

10 Suppl 1

http://www.w3.org/2001/XMLSchema#string

P577

2005-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7575185

http://www.w3.org/2001/XMLSchema#string

P698

16188654

http://www.w3.org/2001/XMLSchema#string

P921

cardiovascular disease

Platelet function testing in cardiovascular diseases.

about

P2860

P2860

Platelet function testing in cardiovascular diseases.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P5875

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P5875

P698

P921